United Therapeutics Corporation (NASDAQ:UTHR) was downgraded by equities researchers at TheStreet from a “b-” rating to a “c” rating in a note issued to investors on Friday.

Several other research firms have also issued reports on UTHR. UBS AG reissued a “sell” rating and issued a $106.00 target price on shares of United Therapeutics Corporation in a report on Thursday, July 6th. ValuEngine raised shares of United Therapeutics Corporation from a “buy” rating to a “strong-buy” rating in a report on Thursday, July 13th. BidaskClub lowered shares of United Therapeutics Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. Jefferies Group LLC reissued a “sell” rating and issued a $105.00 target price on shares of United Therapeutics Corporation in a report on Friday, July 14th. Finally, Zacks Investment Research lowered shares of United Therapeutics Corporation from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. Six analysts have rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $132.09.

Shares of United Therapeutics Corporation (NASDAQ:UTHR) traded up 1.42% during trading on Friday, reaching $123.95. 216,379 shares of the company traded hands. The company has a market capitalization of $5.38 billion, a P/E ratio of 14.37 and a beta of 1.49. The company’s 50-day moving average price is $124.67 and its 200-day moving average price is $127.05. United Therapeutics Corporation has a 52 week low of $110.90 and a 52 week high of $169.89.

United Therapeutics Corporation (NASDAQ:UTHR) last released its earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $3.61 by ($4.86). The firm had revenue of $444.60 million during the quarter, compared to analysts’ expectations of $391.53 million. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. The company’s revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the company posted $4.42 earnings per share. Equities research analysts forecast that United Therapeutics Corporation will post $10.60 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “United Therapeutics Corporation (UTHR) Downgraded by TheStreet” was originally reported by American Banking News and is owned by of American Banking News. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2017/10/05/united-therapeutics-corporation-uthr-downgraded-by-thestreet.html.

In related news, CEO Martine A. Rothblatt sold 1,265 shares of the firm’s stock in a transaction on Thursday, September 28th. The stock was sold at an average price of $119.70, for a total value of $151,420.50. Following the completion of the sale, the chief executive officer now directly owns 2,334 shares in the company, valued at $279,379.80. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Christopher Causey sold 580 shares of the firm’s stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $134.48, for a total value of $77,998.40. Following the completion of the sale, the director now owns 3,295 shares of the company’s stock, valued at $443,111.60. The disclosure for this sale can be found here. Insiders have sold a total of 16,462 shares of company stock valued at $2,097,116 over the last quarter. Corporate insiders own 7.80% of the company’s stock.

Large investors have recently added to or reduced their stakes in the company. Ladenburg Thalmann Financial Services Inc. lifted its position in shares of United Therapeutics Corporation by 11.3% during the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 717 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 73 shares during the last quarter. Daiwa Securities Group Inc. lifted its position in shares of United Therapeutics Corporation by 16.7% during the second quarter. Daiwa Securities Group Inc. now owns 1,050 shares of the biotechnology company’s stock worth $111,000 after purchasing an additional 150 shares during the last quarter. Focused Wealth Management Inc bought a new stake in shares of United Therapeutics Corporation during the fourth quarter worth $115,000. Nordea Investment Management AB lifted its position in shares of United Therapeutics Corporation by 18.7% during the second quarter. Nordea Investment Management AB now owns 1,208 shares of the biotechnology company’s stock worth $128,000 after purchasing an additional 190 shares during the last quarter. Finally, Advisory Services Network LLC bought a new stake in shares of United Therapeutics Corporation during the first quarter worth $147,000.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Analyst Recommendations for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.